UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July 2023
Commission File Number: 001-12033
Nymox Pharmaceutical Corporation |
(Translation of registrant’s name into English) |
Bay & Deveaux Streets, Nassau, The Bahamas
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On July 5, 2023, Nymox Pharmaceutical Corporation (the “Company”) issued a press release announcing receipt of a Nasdaq Hearing Delist Decision noting that the Company has not regained the required $1.00 share price within the 6-month extension period granted by The Nasdaq Stock Market LLC (“Nasdaq”), and hence the Company's shares will be suspended from trading on Nasdaq at the open of business on July 7, 2023. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.
The press release furnished as Exhibit 99.1 to this report on Form 6-K shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
Exhibit No. |
| Description |
|
|
|
| Press Release of Nymox Pharmaceutical Corporation, dated July 5, 2023 |
2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 5, 2023
NYMOX PHARMACEUTICAL CORPORATION | |||
By: | /s/ Paul Averback | ||
| Name: | Paul Averback | |
Title: | President and Chief Executive Officer |
3 |